Aditxt Stock Set to Reverse Split on Monday, November 3rd (NASDAQ:ADTX)

Aditxt, Inc. (NASDAQ:ADTX)’s stock is scheduled to reverse split before the market opens on Monday, November 3rd. The 1-113 reverse split was announced on Wednesday, October 29th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, October 31st.

Aditxt Stock Down 12.5%

Shares of Aditxt stock opened at $0.11 on Thursday. The business’s 50 day moving average is $0.77 and its 200-day moving average is $1.26. Aditxt has a 12-month low of $0.09 and a 12-month high of $147.50. The stock has a market cap of $570,210.00, a P/E ratio of 0.00 and a beta of 1.48.

Aditxt (NASDAQ:ADTX) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($3.45) EPS for the quarter. Aditxt had a negative net margin of 206,431.38% and a negative return on equity of 316.98%.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aditxt in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Trading of Aditxt

An institutional investor recently raised its position in Aditxt stock. IFP Advisors Inc raised its holdings in Aditxt, Inc. (NASDAQ:ADTX) by 66,926.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,054 shares of the company’s stock after buying an additional 10,039 shares during the period. IFP Advisors Inc owned about 17.64% of Aditxt worth $45,000 at the end of the most recent quarter. Institutional investors and hedge funds own 15.54% of the company’s stock.

Aditxt Company Profile

Aditxt, Inc, a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.